ReviewGenes & cancer2016
Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.
Review in Genes & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Reduced structural rigidity of MDMX protein enhances binding to TP53 mRNA.Bioscience reports · 2025Article
- Bringing p53 Back: A Prion-Powered Attack on Retinoblastoma.International journal of biological sciences · 2025Article
- Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.Genes & cancer · 2025Article
- Bioinformatics analysis proposes a possible role for long noncoding RNA MIR17HG in retinoblastoma.Cancer reports (Hoboken, N.J.) · 2024Article
- Review
- Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug.Frontiers in oncology · 2023Review
- Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.Frontiers in pharmacology · 2023Article
- Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.Cancers · 2022Review
- Molecular Mechanism of Tanshinone against Prostate Cancer.Molecules (Basel, Switzerland) · 2022Review
- Epigenetic Silencing ofInternational journal of molecular sciences · 2022Article
- Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain.Biomolecules · 2022Article
- Identification of Epigenetically Modified Hub Genes and Altered Pathways Associated With Retinoblastoma.Frontiers in cell and developmental biology · 2022Article
- Article
- miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.Leukemia · 2021Article
- LINC01116 promotes the proliferation and invasion of glioma by regulating the microRNA‑744‑5p‑MDM2‑p53 axis.Molecular medicine reports · 2021Article
- MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.Scientific reports · 2021Observational
- Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.Frontiers in pharmacology · 2021Review
- Article
- Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells.Cell death and differentiation · 2020Article
- Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.Seminars in cell & developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The orchestrated crosstalk between the retinoblastoma (RB) and p53 pathways contributes to preserving proper homeostasis within the cell. The deregulation of one or both pathways is a common factor in the development of most types of human cancer. The proto-oncoproteins MDMX and MDM2 are the main regulators of the well- known tumor suppressor p53 protein. Under normal conditions, MDM2 and MDMX inhibit p53, either via repression of its transcriptional activity by protein-protein interaction, or via polyubiquitination as a result of MDM2-E3 ubiquitin ligase activity, for which MDM2 needs to dimerize with MDMX. Under genotoxic stress conditions, both become positive regulators of p53. The ATM-dependent phosphorylation of MDM2 and MDMX allow them to bind
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.